secwatch.observer — SEC 8-K summary
======================================

Issuer:     PETMED EXPRESS INC (PETS)
CIK:        0001040130
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001040130-24-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PetMed Express Q1 net income $3.8M on $8.7M stock comp reversal; sales down 13%
-------------------------------------------------------------------------------

- Net sales $68M, down 13% YoY; net income $3.8M ($0.18 diluted) vs loss of $(1.1M) ($(0.06)) prior year.
- Net income increase driven by $8.7M reversal of stock compensation expense from former CEO departure.
- Adjusted EBITDA $(1.5M), $4.9M lower than prior year, due to lower sales and gross profit.
- New CEO Sandra Campos, plus CMO, COO, CDTO appointed; cost reduction and operational streamlining underway.
- Management sees Q1 as transition quarter; early positive indicators from customer growth strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000065/0001040130-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000065/pets-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001040130-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer